76 results on '"Boyle, Brendan"'
Search Results
2. Machine Learning-Based Prediction of Pediatric Ulcerative Colitis Treatment Response using Diagnostic Histopathology
3. Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn’s Disease: A Pragmatic Randomized Trial
4. Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis
5. Single Center Analysis of Essential Laboratory Testing in Patients with Newly Diagnosed Celiac Disease
6. Beta Blockers Are Associated With Reduced All-cause Mortality Among HFpEF Patients
7. Comparative Effectiveness of Anti-TNF in Combination with Low Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn's Disease: A Pragmatic Randomized Trial
8. Su1585: BIOMARKERS OF DRUG CLEARANCE IN PEDIATRIC IBD – A REAL-WORLD VEDOLIZUMAB PHARMACOKINETIC STUDY
9. Su1120: LONG NCRNA LANDSCAPE IN THE RECTUM OF TREATMENT NAÏVE EARLY ONSET ULCERATIVE COLITIS HIGHLIGHTS ASSOCIATION WITH SEVERITY AND EARLY AND LATE DISEASE OUTCOME, WITH POTENTIAL ROLE IN EPITHELIAL METABOLIC FUNCTIONS
10. Use of Patient-Reported Outcomes Measurement Information System Pediatric Measures as Clinical Trial Endpoints: Experience from a Multicenter Pragmatic Trial in Children with Crohn’s Disease
11. REAL-WORLD VEDOLIZUMAB PHARMACOKINETIC STUDY IN CHILDREN IDENTIFIES TWO NOVEL BIOMARKERS OF DRUG CLEARANCE
12. EQUIVALENT ADVERSE OUTCOMES FOR HOME AND HOSPITAL-BASED INFUSIONS OF INFLIXIMAB IN CHILDREN AND ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE
13. Stratification of risk of progression to colectomy in ulcerative colitis via measured and predicted gene expression
14. 727 ANTI-TNF PHARMACOKINETICS AND RESPONSE TO THERAPY IN PEDIATRIC ACUTE SEVERE ULCERATIVE COLITIS (THE ARCH STUDY)
15. Su519 SHOTGUN METAGENOMICS IDENTIFIES MICROBIAL SIGNATURE CHANGES ASSOCIATED WITH INDUCTION INFLIXIMAB CLEARANCE IN CROHN'S DISEASE
16. 423 TARGETED ASSESSMENT OF MUCOSAL IMMUNE GENE EXPRESSION PREDICTS CLINICAL OUTCOMES IN CHILDREN WITH ULCERATIVE COLITIS
17. 728 PLASMA PROTEOMIC RESPONSE SIGNATURE FOR CHILDREN RECEIVING INFLIXIMAB FOR CROHN'S DISEASE
18. Team innovative capability: Does positive mood unlock the innovative potential of environmental cues?
19. ANTI-TNF PHARMACOKINETICS AND RESPONSE TO THERAPY IN PEDIATRIC ACUTE SEVERE ULCERATIVE COLITIS (THE ARCH STUDY)
20. Su1219 GUT MICROBIAL STRAINS AND METABOLITES IN DISEASE COURSE OF PEDIATRIC ULCERATIVE COLITIS
21. 1160 REAL-WORLD PEDIATRIC INFLIXIMAB PHARMACOKINETIC MODEL VERIFIES CRITICAL NEED FOR PRECISION DOSING SOFTWARE
22. Mo1892 PREDICTING SUB-OPTIMAL TRANSITIONS IN ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASES
23. 1161 CLINICAL AND HOST BIOLOGICAL FACTORS CAN PREDICT COLECTOMY RISK IN CHILDREN NEWLY DIAGNOSED WITH ULCERATIVE COLITIS
24. Mo1903 HIGH RATES OF SURGERY PERSIST FOR CHILDREN PRESENTING WITH INTERNAL PENETRATING CROHN'S DISEASE: OBSERVATIONS FROM A MULTICENTER STUDY
25. 613 ANTIBODIES TO INFLIXIMAB ACCELERATE DRUG CLEARANCE WHILE INTENSIFICATION STRATEGIES REVERSE IMMUNOGENICITY AND RECAPTURE CLINICAL RESPONSE
26. 22 CHANGE IN FECAL CALPROTECTIN AND LACTOFERRIN PREDICT CLINICAL REMISSION FOLLOWING INDUCTION THERAPY WITH INFLIXIMAB IN PEDIATRIC CROHN’S DISEASE (CD)
27. A Celiac Care Index Improves Care of Pediatric Patients Newly Diagnosed with Celiac Disease
28. Su1790 – Infliximab Rescue Less Effective in Preventing Colectomy Early in the Course of Newly Diagnosed Ulcerative Colitis
29. 302 – Early Change in Fecal Calprotectin Predicts One Year Clinical Outcome in Children Newly Diagnosed with Ulcerative Colitis
30. 235 – Early Infliximab Pharmacokinetics and Week One Clinical Response in Pediatric Acute Severe Ulcerative Colitis: the Arch Study
31. Tu1760 – Alterations in Expression Quantitative Trait Loci from Diagnosis to Recovery in Pediatric Ulcerative Colitis
32. Tu1290 – Relationships Between Clinical Characteristics, Treatment, and Histological Remission in a Pediatric Eosinophilic Esophagitis Cohort
33. Tu1756 – The Treatment Naive Rectal Transcriptome Identifies Pathways Underlying Response to Induction Corticosteroid Therapy in Ulcerative Colitis
34. Mo1796 – Vedolizumab Experience in Children and Adolescents with Inflammatory Bowel Disease: A Multicenter Observational Study (VOLCANO)
35. Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study
36. Troponin I Tyrosine Phosphorylation: Novel Regulator of Cardiac Function
37. The transfer of HRM practices from emerging Indian IT MNEs to their subsidiaries in Australia: The MNE diamond model
38. Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course
39. Biologics Delay Progression of Crohn’s Disease, but Not Early Surgery, in Children
40. Paraoxonase 2 prevents the development of heart failure
41. 497 - Irrespective of Initial Ulcerative Colitis Therapy Thiopurines Unlikely to Result in Corticosteroid-Free Remission One Year after Diagnosis
42. 589 - The Treatment Naive Rectal Transcriptome Identifies Pathways Mediating Clinical and Endoscopic Severity and Response to Initial Therapy in Pediatric Ulcerative Colitis
43. Su2018 - Longitudinal Adherence to Mesalamine in Pediatric Ulcerative Colitis: Results from the Protect Study
44. 498 - Defining Remission in Pediatric Ulcerative Colitis: Evidence from the Protect Study
45. Sa2009 - Bioavailable Serum Vitamin D and Rectal Vitamin D Receptor Expression at Diagnosis in Pediatric Ulcerative Colitis: Associations with Disease Severity, Clinical Outcomes, and Rectal Patterns of Gene Expression
46. 634 - Gut Microbial Factors Implicated in Disease Progression and Treatment Response in Pediatric Ulcerative Colitis
47. Su2026 - Continued Statural Growth in Older Adolescents and Young Adults with Crohn's Disease and Ulcerative Colitis Beyond the Time of Expected Growth Plate Exposure
48. Tu1791 - An Expression Based Risk Score for Prediction of Colectomy in Pediatric Ulcerative Colitis
49. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study
50. 54 High Frequency of Non-Classical Endoscopic Findings in Children and Adolescents Diagnosed With Ulcerativ E.Coli Tis. The Protect Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.